throbber
Drug Evaluation
`
`Drugs 32: 15-47 (1986)
`0012-6667/86/0007-0015/$16.50/0
`© ADIS Press Limited
`All rights reserved.
`
`Omeprazole
`A Preliminary Review of its Pharmacodynamic and
`Pharmacokinetic Properties, and Therapeutic Potential in
`Peptic Ulcer Disease and Zollinger-Ellison Syndrome
`
`Stephen P. Clissold and Deborah M. Campoli-Richards
`ADIS Drug Information Services, Auckland
`
`Various sections of the manuscript reviewed by: W. BeU, Abteilung Allgemeine Phar(cid:173)
`makologie, Medizinische Hochschule Hannover, Hannover, W. Germany; T. Berglindh,
`Center for Ulcer Research and Education, UCLA School of Medicine, Los Angeles, Cal(cid:173)
`ifornia, USA; J.D. Gardner, Department of Health & Human Services, National Institute
`of Health, Bethesda, Maryland, USA; C. W. Howden, Department of Materia Medica,
`Stobhill General Hospital, Glasgow, Scotland; M .J.S. Langman, Department of Thera(cid:173)
`peutics, University Hospital, Nottingham, England; W. Londong, Medizinische Klinik
`Innenstadt, University of Munich, Munich, West Germany; D.W. Piper, Royal North
`Shore Hospital, St Leonards, New South Wales, Australia; R.E. Pounder, Academic De(cid:173)
`partment of Medicine, The Royal Free Hospital, London, England; G. Sachs, Center for
`Ulcer Research and Education, UCLA School of Medicine, Los Angeles, California, USA;
`K.-Fr. Sewing, Abteilung Allgemeine Pharmakologie, Medizinische Hochschule Han(cid:173)
`nover, Hannover, W. Germany; B. Simon, Gastroenterologische Abteilung, Medizinische
`Universitatsklinik, Heidelberg, W. Germany; A. Waliln, Department of Internal Medi(cid:173)
`cine, University Hospital, Link6ping, Sweden; R.P. Walt, Department of Therapeutics,
`University Hospital, Nottingham, England; K.G. Wormsley, Ninewells Hospital, Ninew(cid:173)
`ells, Dundee, Scotland; N.D. Yeomans, Department of Medicine, Austin Hospital, Hei(cid:173)
`delberg, Victoria, Australia.
`
`Contents
`
`Summary ....................................................................................................................................... 16
`I. Pharmacodynamic Studies ...................................................................................................... 19
`1.1 Site and Mechanism of Action of Omeprazole .............................................................. 19
`1.1 .1 Site of Action ........................................................................................................... 20
`1.1.2 Mechanism of Action .............................................................................................. 21
`1.2 Effects on Gastric Acid Secretion .................................................................................... 23
`1.2.1 Animal Studies ......................................................................................................... 23
`1.2.2 Studies in Healthy Volunteers ................................................................................ 23
`1.2.3 Studies in Patients with Duodenal Ulcer Disease ................................................ 25
`1.2.4 Studies in Patients with Zollinger-Ellison Syndrome ........................................... 26
`1.3 Effects on Other Gastric Juice Constituents .................................................................. 26
`1.3.1 Pepsin ........................................................................................................................ 26
`1.3.2 Intrinsic Factor ......................................................................................................... 27
`1.4 Effects on Gastrointestinal Hormones ............................................................................ 27
`1.4.1 Serum Gastrin .......................................................................................................... 27
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 1
`
`

`

`Omeprazole: A Preliminary Review
`
`16
`
`Summary
`
`1.4.2 Other Gastrointestinal Hormones .......................................................................... 28
`1.5 Effects on Gastric Emptying Rate ................................................................................... 28
`1.6 Effects on Endocrine Function ........................................................................................ 28
`1.7 Prevention of Experimental Gastric Mucosal Damage ................................................. 28
`1.8 Effects on Gastric Mucosal Morphology ........................................................................ 29
`1.9 Effects on Intragastric Bacterial Activity and Nitrosamine Concentrations ................ 31
`2. Pharmacokinetic Studies ......................................................................................................... 31
`2.1 Absorption, Plasma Concentrations, and Bioavailability .............................................. 31
`2.2 Distribution ....................................................................................................................... 33
`2.3 Metabolism and Excretion ............................................................................................... 34
`2.3.1 Elimination Half-Life ............................................................................................... 34
`2.4 Studies in Patients with Duodenal Ulcer Disease or Zollinger-Ellison Syndrome ..... 35
`2.5 Studies in Patients with Chronic Renal Disease ............................................................ 35
`2.6 Relationship Between Plasma Concentration and Antisecretory Activity ................... 35
`3. Therapeutic Trials ................................................................................................................... 35
`3.1 Treatment of Duodenal Ulcers ........................................................................................ 36
`3.1.1 Dose-Ranging Studies .............................................................................................. 36
`3.1.2 Open Studies ............................................................................................................ 36
`3.1.3 Omeprazole Compared with Cimetidine or Ranitidine ....................................... 37
`3.2 Treatment of Ulcerative Peptic Oesophagitis ................................................................. 38
`3.3 Treatment of Gastric Ulcers ............................................................................................ 39
`3.4 Treatment of Zollinger-Ellison Syndrome ...................................................................... 39
`4. Side Effects and Effects on Laboratory Variables ................................................................ 40
`5. Drug Interactions ..................................................................................................................... 41
`6. Dosage and Administration ................................................................................................... .42
`7. Place of Omeprazole in Therapy .......................................................................................... .42
`
`Synopsis: Omeprazolel is a substituted benzimidazole derivative which markedly in(cid:173)
`hibits basal and stimulated gastric acid secretion. It has a unique mode of action. irre(cid:173)
`versibly blocking the so-called proton pump of the parietal cell which is supposedly the
`terminal step in the acid secretory pathway.
`In animals. on a weight basis. omeprazole is 2 to 10 times more potent than cimetidine
`in inhibiting gastric acid secretion. Toxicological studies in rats have shown that very high
`doses of omeprazole administered for 2 years produce hyperplasia of gastric enterochro(cid:173)
`maffin-like cells and carcinoids, a few with proliferations into the submucosa. The sig(cid:173)
`nificance of such findings to the clinical situation is wholly speculative and requires further
`research. Preliminary studies in patients with duodenal ulcers or Zollinger-Ellison syn(cid:173)
`drome have found no mucosal changes which would suggest that the drug represents a
`risk for development of carcinoid tumours at therapeutic dosages.
`In patients with duodenal ulcers omeprazole. at dosages of at least 20mg once daily.
`produced ulcer healing rates of between 60 and 100% after 2 weeks and between 90 and
`100% after 4 weeks. even in patients resistant to treatment with Hrreceptor antagonists.
`Comparative trials clearly demonstrated that omeprazole 20 to 40mg administered once
`daily was significantly more effective than usual dosage regimens of cimetidine and ran(cid:173)
`itidine in healing duodenal ulcers during 2 to 4 weeks of treatment. At present no data
`are available evaluating omeprazole as maintenance therapy once ulcers have healed.
`Other clinical trials have also shown that omeprazole is effective for treating gastric ulcers.
`ulcerative peptic oesophagitis. and Zollinger-Ellison syndrome. In patients with Zollinger(cid:173)
`Ellison syndrome the profound and long lasting antisecretory activity of omeprazole may
`make it the drug of choice for treating the massive acid hypersecretion associated with
`the disease. especially when H2-receptor antagonists are ineffective. During clinical trials
`
`I
`
`'Losee', 'Lozec', 'Losek' (AB Hassle, Astra; not yet commercially available).
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 2
`
`

`

`Omeprazole: A Preliminary Review
`
`17
`
`reported to date omeprazole has been very well tolerated but further clinical experience is
`essential to fully evaluate its safety profile.
`Thus. omeprazolerepresents a pharmacologically unique antisecretory drug which is
`very effective for rapidly healing peptic ulcers and peptic oesophagitis. and for reducing
`gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. If the apparent
`absence of undesirable mucosal morphological changes during treatment with usual doses
`in patients with peptic ulcer disease is confirmed. it may be a major advance in the treat(cid:173)
`ment of these diseases.
`
`Pharmacodynamic Studies: In vitro and in vivo animal studies demonstrated that ome(cid:173)
`prazole produces long lasting inhibition of gastric acid secretion which is likely due to
`non-competitive binding ofa proton-activated derivative to parietal cell (H+fK+)-ATPase.
`Such a mechanism, at the terminal stage of the acid secreting process, means a reduction
`of intragastric acidity can now be achieved independent of the nature of the primary
`stimulus. Comparative studies in animals found omeprazole to be some 2 to 10 times
`more potent than cimetidine on a weight basis.
`Single-dose studies in man (healthy volunteers and patients with duodenal ulcer dis(cid:173)
`ease or Zollinger-Ellison syndrome) have shown that omeprazole inhibits both basal and
`stimulated gastric acid secretion in a dose-dependent manner. Following repeat once daily
`administration, omeprazole has an increasing effect on acid secretion which appears to
`stabilise after about 3 days. Short term studies indicate that 20 to 30mg once daily is the
`optimum dosage regimen in healthy volunteers and patients with duodenal ulcer disease
`in remission; this virtually abolishes gastric acidity within 6 hours and reduces stimulated
`acid output after 24 hours by 60 to 70%.
`In addition to its effects on gastric acidity, omeprazole reduces the total volume of
`gastric juice secreted and inhibits pepsin output. However, these changes are not as con(cid:173)
`sistent or as great as the effect on acid secretion. Omeprazole 0.35 mg/kg administered
`intravenously did not significantly affect basal or stimulated intrinsic factor secretion.
`Furthermore, omeprazole does not seem to have any significant influence on gastric
`emptying rate, or on the majority of gastrointestinal hormones - apart from gastrin. Short
`periods of treatment with omeprazole administered once daily usually resulted in ele(cid:173)
`vated serum gastrin levels. Such hypergastrinaemia occurs secondary to a pronounced
`reduction of intragastric acidity, and returns to normal levels within I to 2 weeks of
`. stopping treatment.
`Orally, but not parenterally, administered omeprazole seems to be cytoprotective in
`some animal models of peptic ulcer disease such as Shay ulcers, stress-induced ulcers,
`and ulcers induced by various necrotising agents. The mechanisms involved are not fully
`understood but appear to be independent of the established anti secretory properties of
`omeprazole.
`Toxicological studies in rats have demonstrated that supramaximal doses of orne(cid:173)
`prazole administered for long periods cause gastric enterochromaffin-Iike cell hyperplasia
`and carcinoids, a few with proliferations into the submucosa. It has been suggested that
`hypergastrinaemia, induced by the profound inhibition of gastric secretion causes these
`changes; their relevance to the therapeutic use of omeprazole remains speculative and
`further studies are required.
`
`Pharmacokinetic Studies: The absorption characteristics of omeprazole are both form(cid:173)
`ulation- and dose-dependent. Following administration of the drug as a buffered oral
`solution, buffered encapsulated uncoated granUles, or as capsules of enteric-coated gran(cid:173)
`ules, mean peak plasma omeprazole concentrations were attained after 20 minutes, 30
`minutes, and between 2 and 5 hours, respectively. Interestingly, increased doses of ome(cid:173)
`prazole produced disproportionately larger increases in mean peak plasma concentration
`and systemic availability. Similarly, repeat once daily administration for 5 to 7 days
`resulted in significant elevations of mean peak plasma concentration and area under the
`plasma concentration-time curve. Since omeprazole is acid labile, these findings could
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 3
`
`

`

`Omeprazole: A Preliminary Review
`
`18
`
`possibly indicate that the antisecretagogue improves its own absorption and relative bio(cid:173)
`availability by inhibiting acid secretion. An alternative explanation involves saturation
`of enzymes responsible for the first-pass metabolism of omeprazole.
`Following intravenous administration omeprazole plasma concentrations decline
`biexponentially. The apparent volume of distribution of omeprazole is about 0.3 to 0.4
`L/kg which is compatible with localisation of the drug in extracellular water. Penetration
`of omeprazole into red blood cells is low, whereas its plasma protein binding is high -
`between 95 and 96% in human plasma.
`Omeprazole is eliminated rapidly and almost completely by metabolism; no un(cid:173)
`changed drug has been recovered in the urine. Following absorption, 3 metabolites of
`omeprazole have been identified: a sulphone derivative, a sulphide derivative and hy(cid:173)
`droxyomeprazole. Peak plasma concentrations of the sulphone metabolite are attained
`shortly after those of unchanged omeprazole, 0.4 to 1.7 hours after peak omeprazole
`concentrations following administration of capsules of enteric-coated granules. However,
`unidentified metabolites of omeprazole had a very similar plasma concentration-time
`curve as the parent drug - in terms of peak concentration and the time to achieve it.
`Following administration of 14C-omeprazole approximately 60% of total radioactivity is
`recovered in the urine within 6 hours. Over a ~y period about 80% of the administered
`dose was recovered in the urine and the remainder in the faeces. Total plasma clearance
`is relatively high (32 to 40 L/h) and most studies have reported a mean elimination half(cid:173)
`life of omeprazole in healthy subjects of between 0.5 and 1.5 hours (usually about I
`hour).
`There are limited data available concerning the pharmacokinetic properties of ome(cid:173)
`prazole in patients with peptic ulcer disease or Zollinger-Ellison syndrome.
`The pharmacokinetic profile of omeprazole does not seem to be altered in patients
`with chronic renal failure and is not influenced by haemodialysis.
`Omeprazole plasma concentration does not correlate with its antisecretory activity at
`a given time-point; indeed, the drug markedly inhibits acid secretion long after plasma
`concentrations have decreased below detection limits. However, there does seem to be
`a significant correlation between antisecretory activity and area under the plasma con(cid:173)
`centration-time curve.
`
`Therapeutic Trials: Clinical trials have demonstrated that omeprazole at dosages of
`at least 20mg once daily produces a duodenal ulcer healing rate of between 60 and 100%
`within 2 weeks and between 90 and 100% within 4 weeks. Dose-finding studies showed
`that an optimal dosage of omeprazole is between 20 and 40mg once daily. Open clinical
`studies have confirmed these very high rates of duodenal ulcer healing even in a small
`group of patients who were refractory to treatment with H2-receptor antagonists (alone
`or in combination with other antiulcer drug!;). Appropriately designed comparative clinical
`trials clearly demonstrated that once-daily administration of omeprazole 20 to 40mg pro(cid:173)
`duces significantly more rapid healing of duodenal ulcers after 2 to 4 weeks of treatment
`than the H2-receptor antagonists cimetidine and ranitidine. Additionally, omeprazole 20mg
`and 40mg once daily elicited significantly greater symptom relief than ranitidine 150mg
`twice daily, whereas in 2 other studies 30mg and 20mg of omeprazole were indistin(cid:173)
`guishable from cimetidine 1000 mgfday and ranitidine 300 mgfday, respectively, in this
`respect. Other clinical studies have shown that omeprazole administered once daily may
`be effective for treating gastric ulcers and ulcerative peptic oesophagitis. Indeed, ome(cid:173)
`prazole 40mg once daily was significantly superior to ranitidine 150mg twice daily in
`178 patients with reflux oesophagitis. Furthermore, in a double-blind multicentre trial
`in 184 outpatients with gastric ulceration, omeprazole 20mg once daily was as effective
`as ranitidine l50mg twice daily and healed 95% of gastric ulcers within 8 weeks.
`In patients with Zollinger-Ellison syndrome, omeprazole is a highly potent and long
`acting antisecretagogue which many authors consider will become the drug of choice for
`controlling the massive acid hypersecretion associated with the disease. For patients with
`Zollinger-Ellison syndrome who are resistant to H2-receptor antagonists, omeprazole of-
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 4
`
`

`

`Omeprazole: A Preliminary Review
`
`19
`
`fers a valuable therapeutic alternative to surgery (partial or total gastrectomy) with its
`inherent risks.
`
`Side Effects: Preliminary experience with omeprazole has found the antisecretagogue
`to be well-tolerated, producing no consistent side effects or changes in laboratory vari(cid:173)
`ables. Wider clinical usage with careful surveillance is needed to fully evaluate the side
`effect profile of omeprazole.
`
`Dosage and Administration: The usual oral adult dosage of omeprazole seems to be
`20mg once daily before breakfast for 2 to 4 weeks for duodenal ulcers and 4 to 8 weeks
`for gastric ulcers. In patients with Zollinger-Ellison syndrome omeprazole dosage should
`be individualised so that the smallest dose is administered which reduces gastric acid
`secretion to less than 10 mEq for the last hour before the next dose. At present, insuf(cid:173)
`ficient data are available for dosage recommendations in children.
`
`1. Pharmacodynamic Studies
`
`Omeprazole (fig. 1) is a substituted benzimi(cid:173)
`dazole which markedly inhibits basal and stimu(cid:173)
`lated gastric acid secretion in animals and man. It
`is the first of a new class of antiulcer drugs likely
`to be introduced into clinical practice (it is not yet
`commercially available) and is thought to reduce
`acid secretion by inhibiting hydrogen/potassium
`adenosine triphosphatase [(H+/K+)-ATPase), be(cid:173)
`lieved to be the proton pump of the parietal cell.
`This mechanism, at the terminal stage of the acid
`secreting process, means that for the first time in(cid:173)
`tragastric acidity can be reduced independent of the
`nature of the primary stimulus. Since inhibition of
`gastric acid is a most important indicator of the
`therapeutic potential of drugs used to treat peptic
`
`Fig. 1. Structural formula of omeprazole.
`
`ulceration, oIl!eprazole might be expected to offer
`some advantages for the treatment of this disease.
`Independent of its clinical future, omeprazole is al(cid:173)
`ready an important pharmacological 'tool' for in(cid:173)
`vestigating physiological and biochemical changes
`that occur in the gastric mucosa and for evaluating
`the mechanisms of action of gastric acid inhibitors.
`
`1.1 Site and Mechanism of Action of
`Omeprazo1e
`
`Superficially, upper gastrointestinal ulceration
`has a relatively simple underlying aetiology which
`involves some loss of ability of the mucosa to pro(cid:173)
`tect against gastric acid and/or excessive secretion
`of acid. The complex morphological changes that
`occur with regard to mucosal cytoprotection in re(cid:173)
`lation to the various conditions found in the upper
`gut are currently poorly understood and drug treat(cid:173)
`ment has been largely devoted to controlling lu(cid:173)
`minal acidity (Berglindh & Sachs 1985).
`Hydrochloric acid, one major cause of upper
`gastrointestinal tract ulcers, is secreted from par(cid:173)
`ietal (oxyntic) cells by the gastric proton pump
`[gastric (H~/K+)-ATPase], distal to cyclic adeno(cid:173)
`sine monophosphate (cAMP), in response to at least
`3 different types of stimulation - cholinergic (va(cid:173)
`gal), histaminergic and gastrinergic (Sachs 1984)
`[fig. 2]. It follows that an individual antagonist to
`anyone of the 3 (or more) receptor types will only
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 5
`
`

`

`Omeprazole: A Preliminary Review
`
`20
`
`AntimuSC8rinic drugs
`
`Gastric (H+/K+)-ATPase
`inhibitors
`(e.g. omeprazole)
`
`/
`
`/
`
`/
`tI
`
`______ .H+
`
`--1t--------t. K+
`---i"~-----... CI-
`
`(e.g. Pirenzepine), ,
`,..----....,1'·
`t
`---- /~
`
`Acetylcholine
`
`_
`
`Gastrin
`
`)
`
`/
`
`1/
`Histamine> / 1f
`~
`
`/
`
`/
`Histamine H:rreceptor antagonists
`(e.g. clmetidlne and ranltidine)
`
`---Serosa--..... I ... ---Parietal cell---.~ I+--MUCOse--
`
`Fig. 2. A simple conceptual model of the parietal cell and some speculated mechanisms involved in the control and inhibition of
`gastric acid secretion (after Fiasse et al. 1984; Fimmel & Blum 1984; Lewin 1984; Rabon et ai. 1983).- -"'represents proposed
`mechanisms by which certain classes of antiulcer drugs antagonise gastric acid stimulation.- .... indicates other additional effects
`of the H2-receptor antagonists (although it is not necessarily at the receptor level) which may contribute to their antisecretory activity
`(for a review see Bowman & Rand 1980).
`
`partially block gastric acid secretion although there
`is evidence that the histamine-stimulated system
`may be dominant since histamine Hz-receptor ant(cid:173)
`agonists (cimetidine and ranitidine) seem capable
`of inhibiting a major portion of gastric acid secre(cid:173)
`tion. However, inhibition of the gastric proton
`pump, probably the terminal stage of the acid se(cid:173)
`creting pathway from the parietal cell, provides a
`means of blocking gastric acid secretion by a greater
`amount. This is the proposed site and mechanism
`of action of omeprazole (Berglindh & Sachs
`1985; Helander et al. 1985; Larsson et al. 1985b)
`[fig. 2].
`
`1.1.1 Site of Action
`Parietal cells are buried deep within the gastric
`mucosa (slightly beneath peptic cells). Their secre(cid:173)
`tory surfaces are covered with microvilli and are
`deeply invaginated to form channels termed can(cid:173)
`aliculi. The gastric proton pump [(H+/K+)(cid:173)
`ATPase], which has been discovered in frog (Gan(cid:173)
`ser & Forte 1973), hog (Saccomani et al. 1975) and
`human (Saccomani et al. 1979) gastric mucosa, has
`been isolated mostly from parietal cells although
`there is some evidence that it may be present in
`jejunal (White 1985) and colonic (Gustin & Good(cid:173)
`man 1981) mucosa. In gastric mucosa the proton
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 6
`
`

`

`Omeprazole: A Preliminary Review
`
`21
`
`pump is situated in the apical membrane and tub(cid:173)
`ulovesicles bordering the secretory canaliculi of the
`parietal cell (for reviews see Berglindh & Sachs
`1985; Olbe et al. 1979). Consequently, each can(cid:173)
`aliculus can be viewed as an invaginated extracel(cid:173)
`lular compartment of low pH (about pH 1). Such
`an environment should readily accumulate weak
`bases with a pKa higher than the pH of the gastric
`compartment (Berglindh & Sachs 1985; Sachs
`1984).
`Omeprazole is a substituted benzimidazole and
`a weak base (pKa = 3.97), which fulfills the criteria
`for accumulation within the acid space (Briind(cid:173)
`strom et al. 1985). Animal studies have provided
`strong evidence that the main site of action of
`omeprazole is indeed in the distal (to cAMP) por(cid:173)
`tion of the parietal cell. Thus, radiolabelled ome(cid:173)
`prazole administered intravenously to mice was
`shown to accumulate rapidly in gastric mucosa,
`liver, kidney, and in the choroid plexus, but after
`16 hours high levels of radioactivity remained only
`in the gastric mucosa. Autoradiography revealed
`that it was localised in the parietal cells and sub(cid:173)
`sequent electron microscopic autoradiography
`demonstrated that the radioactive label was almost
`exclusively found at the secretory surfaces and their
`immediate vicinity, and in regions of cytoplasm
`containing the tubulovesicles (Helander et al. 1983,
`1985).
`Fryklund et al. (1984) using separated and en(cid:173)
`riched parietal and chief cell fractions from rabbit
`gastric mucosa showed that omeprazole had a spe(cid:173)
`cific inhibitory effect on acid secretion from par(cid:173)
`ietal cells and did not influence stimulated release
`of pepsinogen from chief cells. However, DeflZe et
`al. (1985) found that omeprazole 0.1 mmol/L
`strongly stimulated secretion of preformed and re(cid:173)
`cently synthesised pepsinogen in isolated rabbit
`gastric glands even though it decreased pepsinogen
`synthesis. Similarly, Fimmel et al. (1984) observed
`that omeprazole 0.1 mmol/L stimulated pepsin re(cid:173)
`lease in the in vitro perfused mouse stomach model;
`the mechanism remains uncertain although the in(cid:173)
`crease does not seem to be due to a nonspecific
`leakage through disruption of chief cell membranes
`(Defize et al. 1985).
`
`The above findings and those from additional
`in vitro experiments (see section 1.1.2) clearly in(cid:173)
`dicate that the main site of action of omeprazole
`is in the parietal cell at a point distal to cAMP. It
`seems likely that the drug binds with (H+/K+)(cid:173)
`ATPase in the cytoplasm/tubulovesicles and secre(cid:173)
`tory surfaces bordering the canaliculi. However,
`Keeling et al. (1985) and Beil and Hackbarth (1985)
`demonstrated that omeprazole also inhibits (Na+ /
`K+)-ATPase isolated from dog kidneys, but to a
`lesser extent than its effects on (H+/K+)-ATPase.
`The authors noted that the acidic compartments of
`the parietal cell would impart a high degree of se(cid:173)
`lectivity onto omeprazole. Further evidence for the
`specificity of action of omeprazole is provided by
`Howden and Reid (1984) who reported that the
`drug had no demonstrable effects on renal electro(cid:173)
`lyte or renal acid excretion in healthy volunteers.
`
`1.1.2 Mechanism of Action
`Various in vitro preparations ranging from iso(cid:173)
`lated gastric mucosa to purified (H+fK+)-ATPase
`from parietal cells have been utilised to help define
`the mechanism of action of omeprazole (Wallmark
`et al. 1983, 1985). As can be seen in table I, ome(cid:173)
`prazole inhibits both basal and stimulated acid se(cid:173)
`cretion (irrespective of whether acid formation was
`stimulated by histamine, cAMP, high K+ levels, or
`exogenously added ATP). In contrast, cimetidine
`only antagonised histamine-stimulated gastric acid
`secretion which is consistent with its Hrreceptor
`blocking properties. Omeprazole and thiocyanate
`shared many common pharmacodynamic actions,
`although only omeprazole directly inhibited iso(cid:173)
`lated (H+/K+)-ATPase and Withstood attempted
`reversal by antipyrine of its acid inhibitory prop(cid:173)
`erties in isolated gastric mucosa. These findings
`highlight the late stage in the acid secreting process
`at which omeprazole exerts its inhibitory effects.
`The potency of omeprazole is markedly en(cid:173)
`hanced in an acidic environment (Beil & Hack(cid:173)
`barth 1985; Beil & Sewing 1985; Beil et al. 1985;
`1m et al. 1985b,c; Keeling et al. 1985; Wallmark et
`al. 1983, 1984, 1985, 1986). This CQuld be due to
`a change in parietal cell (H+/K+)-ATPase making
`it more susceptible to the effects of omeprazole at
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 7
`
`

`

`Omeprazole: A Preliminary Review
`
`22
`
`Table I. Summary of in vitro studies designed to elucidate the mechanism of action of omeprazole, compared with cimetidine and
`thiocyanate as reference drugs, with regard to inhibition of gastric acid secretion (after Beil & Sewing 1984; Larsson & Ryberg 1983;
`Larsson et a!. 1984; Sewing et a!. 1983; Wallmark et a!. 1983, 1985)
`
`Preparation
`
`Guinea-pig isolated gastric mucosa
`
`Rabbit isolated intact gastric glands
`
`Gastric acid
`stimulant
`
`Basal
`Histamine
`Dibutyryl-cAMP
`
`Basal
`Histamine
`Dibutyryl-cAMP
`K+
`
`Rabbit isolated permeable gastric glands ATP, K+
`
`Rabbit isolated parietal cells
`
`Histamine
`Dibutyryl-cAMP
`
`Pig isolated gastric (W/K+)-ATPase
`
`ATP, K+
`
`Guinea-pig (W/K+)-ATPase purified from
`parietal cells
`
`K+
`
`Guinea-pig isolated and enriched parietal Histamine
`cells
`Dibutyryl-cAMP
`
`Inhibitor of gastric acid secretion
`
`omeprazole
`
`cimetidine
`
`thiocyanate
`
`+
`+
`
`+
`+
`+
`+
`+
`
`+
`
`+
`
`+
`
`+
`+
`+
`+
`+
`+
`+
`+
`+
`+
`+
`+
`
`+
`+
`
`Abbreviations: cAMP = cyclic adenosine monophosphate; ATP = adenosine triphosphate; + = drug produced inhibition of gastric
`acid secretion; - = drug did not produce any inhibition of gastric acid secretion.
`
`low pH. However, at present, the weight of evi(cid:173)
`dence suggests that omeprazole is activated at acidic
`pH (probably by protonation) and that the H+-ac(cid:173)
`tivated derivative reacts with sulfhydryl groups as(cid:173)
`sociated with gastric (H+/K+)-ATPase (1m et al.
`I 985b,c; Keeling et al. 1985; Sewing & Hanne(cid:173)
`mann 1985; Wallmark et al. 1984). Beil and Sewing
`found
`that omeprazole could inhibit various
`sulfhydryl-containing A TPases but it was most ef(cid:173)
`fective against gastric (H+/K+)-ATPase. Thus, the
`unique low pH of the tubulovesicles should make
`the actions of omeprazole very specific since ome(cid:173)
`prazole preferentially accumulates at these low pH
`sites and an acid pH is necessary to activate the
`drug.
`A number of research groups have performed
`more detailed studies to determine the structure of
`the active form of omeprazole and the nature of
`its reaction with gastric (H+/K+)-ATPase (1m et al.
`
`1985c; Lorentzon et al. 1985; Rackur et al. 1985;
`Wallmark et al. 1986). Wallmark et al. (1986) re(cid:173)
`cently suggested that omeprazole acts in vivo, after
`being converted in the acid compartments of the
`parietal cell into a sulphenamide derivative, by
`forming a disulphide complex with the enzyme
`(H+/K+)-ATPase. Alternatively, a sulphenic acid
`form of omeprazole may react directly with the en(cid:173)
`zyme. These proposed mechanisms differ from
`those previously suggested by 1m et al. (1985c) and
`Rackur et al. (1985) and further studies are needed
`to elucidate the precise mechanisms involved in
`the inactivation of gastric (H+/K+)-ATPase.
`There is some conflict regarding the nature of
`the omeprazole/(H+/K+)-ATPase interaction. In
`vitro studies have shown that the inhibitory effects
`of omeprazole can be washed out (Berglindh et al.
`1985; Sewing et al. 1983, 1985) or they can be re(cid:173)
`versed by sulfhydryl-reducing compounds such as
`
`MYLAN PHARMS. INC. EXHIBIT 1023 PAGE 8
`
`

`

`Omeprazo)e: A Preliminary Review
`
`23
`
`,B-mercaptoethanol. In vivo experiments demon(cid:173)
`strated that omeprazole produces long lasting in(cid:173)
`hibition of acid secretion which is likely due to ir(cid:173)
`reversible inhibition of parietal cell (H+/K+)(cid:173)
`ATPase (Berglindh et al. 1985; 1m et al. 1985a).
`The discrepancy between in vitro and in vivo re(cid:173)
`sults needs to be explained, although there is evi(cid:173)
`dence that omeprazole irreversibly inactivates (H+/
`K +)-A TPase in vivo and new enzyme has to be syn(cid:173)
`thesised before gastric acid secretory activity can
`be restored (1m et al. 1985a).
`
`binds with (H+/K+)-ATPase in the parietal cell. As
`a consequence of its l

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket